- Home
- SLS vs AGEN Comparison
SLS vs AGEN Comparison
Compare SLS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLS
- AGEN
- Stock Information
- Founded
- SLS 2012
- AGEN 1994
- Country
- SLS United States
- AGEN United States
- Employees
- SLS N/A
- AGEN N/A
- Industry
- SLS Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLS Health Care
- AGEN Health Care
- Exchange
- SLS Nasdaq
- AGEN Nasdaq
- Market Cap
- SLS 100.6M
- AGEN 96.2M
- IPO Year
- SLS N/A
- AGEN 2000
- Fundamental
- Price
- SLS $1.27
- AGEN $3.32
- Analyst Decision
- SLS
- AGEN Buy
- Analyst Count
- SLS 0
- AGEN 3
- Target Price
- SLS N/A
- AGEN $10.50
- AVG Volume (30 Days)
- SLS 4.1M
- AGEN 360.9K
- Earning Date
- SLS 03-27-2025
- AGEN 03-13-2025
- Dividend Yield
- SLS N/A
- AGEN N/A
- EPS Growth
- SLS N/A
- AGEN N/A
- EPS
- SLS N/A
- AGEN N/A
- Revenue
- SLS N/A
- AGEN $160,427,000.00
- Revenue This Year
- SLS N/A
- AGEN N/A
- Revenue Next Year
- SLS N/A
- AGEN $26.02
- P/E Ratio
- SLS N/A
- AGEN N/A
- Revenue Growth
- SLS N/A
- AGEN 59.00
- 52 Week Low
- SLS $0.77
- AGEN $2.50
- 52 Week High
- SLS $1.84
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- SLS 50.97
- AGEN 45.96
- Support Level
- SLS $1.20
- AGEN $3.09
- Resistance Level
- SLS $1.37
- AGEN $3.68
- Average True Range (ATR)
- SLS 0.14
- AGEN 0.25
- MACD
- SLS -0.02
- AGEN -0.03
- Stochastic Oscillator
- SLS 10.94
- AGEN 23.00
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).